3 Asian Stocks Estimated To Be Up To 44.3% Below Intrinsic Value
As Asian markets navigate a complex landscape marked by geopolitical developments and economic shifts, investors are keenly observing opportunities that may arise from undervalued stocks. In this context, identifying stocks trading below their intrinsic value can offer potential for growth, especially when broader market conditions suggest resilience amid global uncertainties.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Yageo (TWSE:2327) | NT$602.00 | NT$1172.73 | 48.7% |
| VINA TECHLtd (KOSDAQ:A126340) | ₩70300.00 | ₩139946.76 | 49.8% |
| Shoucheng Holdings (SEHK:697) | HK$1.70 | HK$3.30 | 48.5% |
| Pan-United (SGX:P52) | SGD1.62 | SGD3.14 | 48.3% |
| Ningbo Sanxing Medical ElectricLtd (SHSE:601567) | CN¥15.85 | CN¥31.65 | 49.9% |
| Livero (TSE:9245) | ¥2140.00 | ¥4238.39 | 49.5% |
| Japan Eyewear Holdings (TSE:5889) | ¥2569.00 | ¥5056.75 | 49.2% |
| gremsInc (TSE:3150) | ¥2462.00 | ¥4921.43 | 50% |
| Contec.Co.Ltd (KOSDAQ:A451760) | ₩8250.00 | ₩16275.20 | 49.3% |
| Baycurrent (TSE:6532) | ¥7379.00 | ¥14376.31 | 48.7% |
Let's review some notable picks from our screened stocks.
ISU Petasys (KOSE:A007660)
Overview: ISU Petasys Co., Ltd. manufactures and sells printed circuit boards (PCBs) and has a market cap of ₩6.61 trillion.
Operations: ISU Petasys Co., Ltd. generates its revenue primarily from the manufacturing and sale of printed circuit boards (PCBs).
Estimated Discount To Fair Value: 44.3%
ISU Petasys is trading at ₩90,100, significantly below its estimated future cash flow value of ₩161,813.91, presenting a strong case for being undervalued based on cash flows. The company's earnings are expected to grow substantially at 38.65% annually over the next three years, outpacing the Korean market's average growth rate. However, investors should note the stock's high volatility in recent months despite its robust financial outlook and high-quality earnings profile.
- The growth report we've compiled suggests that ISU Petasys' future prospects could be on the up.
- Dive into the specifics of ISU Petasys here with our thorough financial health report.
WuXi XDC Cayman (SEHK:2268)
Overview: WuXi XDC Cayman Inc. is an investment holding company that functions as a contract research, development, and manufacturing organization with operations in China, North America, Europe, and internationally; it has a market cap of HK$80.92 billion.
Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to CN¥5.94 billion.
Estimated Discount To Fair Value: 25%
WuXi XDC Cayman is trading at HK$63.9, which is 25% below its estimated future cash flow value of HK$85.19, highlighting its undervaluation based on cash flows. The company anticipates robust revenue growth of 23.7% annually, surpassing the Hong Kong market's average rate. Despite significant insider selling recently, WuXi XDC maintains high-quality earnings and a strong return on equity forecasted at 20.4%, with earnings expected to grow significantly over the next three years.
- Our expertly prepared growth report on WuXi XDC Cayman implies its future financial outlook may be stronger than recent results.
- Delve into the full analysis health report here for a deeper understanding of WuXi XDC Cayman.
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212)
Overview: Shanghai Aohua Photoelectricity Endoscope Co., Ltd. operates in the medical device industry, specializing in the development and production of endoscopic equipment, with a market cap of CN¥4.28 billion.
Operations: The company's revenue from medical devices amounts to CN¥787.64 million.
Estimated Discount To Fair Value: 13%
Shanghai Aohua Photoelectricity Endoscope, priced at CN¥31.8, trades below its future cash flow value of CN¥36.56, offering potential undervaluation based on cash flows. The company forecasts a significant annual earnings growth of 61.13%, outpacing the Chinese market's average. However, one-off items have impacted financial results and its return on equity is expected to be low at 9.4% in three years, which may concern some investors despite good relative value compared to peers and industry standards.
- Our comprehensive growth report raises the possibility that Shanghai Aohua Photoelectricity Endoscope is poised for substantial financial growth.
- Click here and access our complete balance sheet health report to understand the dynamics of Shanghai Aohua Photoelectricity Endoscope.
Turning Ideas Into Actions
- Delve into our full catalog of 213 Undervalued Asian Stocks Based On Cash Flows here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com